Apr 05, 2019 (Market Exclusive via COMTEX) — Sarepta Therapeutics, Inc. SRPT, -1.34% Files An 8-K Other Events
Item 8.01 Other Events.
As previously reported, on May 3, 2018, Sarepta Therapeutics, Inc. (the “Company”) and Myonexus Therapeutics, Inc. (“Myonexus”) entered into a warrant to purchase common stock of Myonexus, which, in combination with amendments to the Myonexus certificate of incorporation, provided the Company with an exclusive option to acquire Myonexus (the “Option”). On February 26, 2019, the Company delivered to Myonexus an exercise notice stating its intention to exercise the Option and on April 4, 2019, the Company exercised the Option and acquired Myonexus. As a result of the exercise, Sarepta is the sole stockholder of Myonexus.
About Sarepta Therapeutics, Inc. SRPT, -1.34%
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.